---Select--- Sort by Relevance Sort by Date(descending) Sort by Date(ascending)
Upsher-Smith
Laboratories Inc ., of Maple Grove, Minn., completed a global Phase III trial for USL255 (extended-release topiramate), an internally developed program for the management of epilepsy in adults
BioWorld Today |
Thursday, May 23, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
Bioscan |
Tuesday, May 21, 2013
---Select--- Sort by Relevance Sort by Date(descending) Sort by Date(ascending)
Upsher-Smith Laboratories Inc., of Maple Grove, Minn., completed a global Phase III trial for USL255 (extended-release topiramate), an internally developed program for the management of epilepsy in adults